Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Dow second quarter sales increase to $16.0 billion

Dow reported earnings of $0.84 per share. This compares with reported earnings of $0.50 per share in the same period last year.

27 Jul 2011

Teleflex second quarter net revenues increase 9.2% to $391.3 million

Teleflex Incorporated today announced financial results for the second quarter and six months ended June 26, 2011.

27 Jul 2011

Repligen first quarter total revenue increases 9% to $7,654,000

Repligen Corporation today reported results for the first quarter of fiscal year 2012, ended June 30, 2011.

27 Jul 2011

Selexis, CSL enter commercial license agreement for therapeutic antibody

Selexis SA, a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins announced today that CSL Limited has entered a commercial license agreement with Selexis for the preclinical development of a therapeutic antibody anticipated to enter Phase I clinical trials in 2012.

26 Jul 2011

Cipher net revenue decreases to $0.7 million for Q2 2011

Cipher Pharmaceuticals Inc. today announced its financial and operational results for the three and six months ended June 30, 2011.

26 Jul 2011

Biogen Idec reports revenue of $1.2 billion for second quarter 2011

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its second quarter 2011 results.

26 Jul 2011

CNBG, Aeras sign MOU to develop TB vaccines in China and around the world

Aeras and the China National Biotech Group (CNBG) today announced the signing of a memorandum of understanding for the organizations to pursue opportunities to jointly develop tuberculosis (TB) vaccines in China and potentially other parts of the world.

26 Jul 2011

Adaptimmune announces opening of pilot clinical trial in synovial sarcoma

Adaptimmune announced today that it has opened a Pilot, open-label clinical trial in synovial sarcoma at the National Cancer Institute (NCI), Bethesda, Maryland, testing its enhanced T cell receptor T cell therapy. A second site is planned to open later this year at Washington University, St. Louis, Missouri.

25 Jul 2011

Genesis Biopharma partners with Lonza for Contego to treat metastatic melanoma

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, and Lonza, today announced the signing of a process development and scale-up agreement relating to the manufacture of Contego™, Genesis Biopharma's autologous cell therapy product candidate for the treatment of Stage IV metastatic melanoma.

25 Jul 2011

Swaziland government, Vantage plan to construct pharmaceutical manufacturing facility

Vantage Health, announced today that it has been invited by the Ministry of Health for the Kingdom of Swaziland to plan the construction of a pharmaceutical manufacturing facility in that country.

25 Jul 2011

MiMedx second quarter revenue increases 85% to $1,929,000

MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the second quarter and six months ended June 30, 2011.

25 Jul 2011

Modern Plastics moves to Shelton, Connecticut

Modern Plastics, one of the largest distributors of high-performance and engineering-grade stock shapes and medical-grade plastics, has moved from its former home in Bridgeport to Shelton, Connecticut. The new address is 88 Long Hill Cross Road, Shelton, Connecticut 06484 USA.

22 Jul 2011

IDEXX Laboratories second quarter revenues increase 13% to $317.9 million

IDEXX Laboratories, Inc., today reported that revenues for the second quarter of 2011 increased 13% to $317.9 million, from $281.5 million for the second quarter of 2010. Organic revenue growth, as defined below, was 8%.

22 Jul 2011

UK regulators approve Europe's first clinical trial of plant-derived antibody for HIV

UK regulators have approved Europe's first clinical trial of a monoclonal antibody produced from genetically modified plants. This landmark decision sets the stage for the testing, in humans, of an anti-HIV product made from genetically modified tobacco plants. It will open the door for trials of additional plant-derived medicines treating a range of diseases.

22 Jul 2011

FDA approves U.S. launch of Wiskott-Aldrich gene therapy clinical trial

The U.S. Food & Drug Administration (FDA) approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome.

22 Jul 2011

Randox win Premier Healthcare Alliance contract for Quality Control

Randox Laboratories Ltd is proud to announce that in April 2011 we signed a multi-year agreement with the Premier Healthcare Alliance for the supply of Acusera Quality Control (QC) materials. The agreement will provide the 90,000 plus Premier members with access to our extensive range of quality control products and the benefits they offer clinical laboratories. When asked about the new agreement Laura Coyle Randox Business Manager for the USA revealed that ‘We look forward to strengthening our relationship with Premier and providing added value to their members’.

From Randox Laboratories Ltd. 21 Jul 2011

Alliqua acquires global license for wound care dressings from Noble Biomaterials

Alliqua, Inc., an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and wound care technologies today announced that it has acquired from Noble Biomaterials, Inc. a 10 year exclusive global license for two wound care dressings, with an additional 10 year renewal option.

21 Jul 2011

Clinical study of anti-HIV antibody made from genetically modified tobacco plants

Pharmaceuticals can be produced by plants. Antibodies that have been produced in tobacco plants will now for the first time be tested in a clinical study.

21 Jul 2011

Localized one-time gene therapy might effectively protect against atherosclerosis

A one-dose method for delivering gene therapy into an arterial wall effectively protects the artery from developing atherosclerosis despite ongoing high blood cholesterol.

21 Jul 2011

Anomatic to open new production facility in New Albany, Ohio

Anomatic Corporation, known for their unique, high volume metal packaging and custom anodizing process for the medical, pharmaceutical, personal care and cosmetic packaging industries, is expanding operations with a brand new facility in New Albany, Ohio.

21 Jul 2011